参考文献
[1]Barber M.,Murrell A.Ito Y.Maia A.T.,Hyland S.Oliveira C.et al.Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer[J].J.Pathol.2008,216,295-306.
[2]Barber M.E.,Save V.,Carneiro F.Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk[J].J.Pathol.2008,216,286-294.
[3]Benusiglio P.R.,Colas C.,Rouleau E.Hereditary diffuse gastric cancer syndrome:improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation[J].J.Med.Genet.2015,52,563-565.
[4]Black M.D.,Kaneshiro R.,Lai J.I.,et al.Hereditary diffuse gastric cancer associated with E-cadherin germline mutation:a case report.Hawaii[J].J.Med.Public Health.2014,73,204-207.
[5]Caggiari L.,Miolo G.,Buonadonna A.,et al.Characterizing metastatic HER2-positive gastric cancer at the CDH1 haplotype[J].Int.J.Mol.Sci,2017,19:47.
[6]Corso G.,Carvalho J.,Marrelli D.,et al.Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer[J].J.Clin.Oncol.2013,31,868-875.
[7]Corso G.,Figueiredo J.,Biffi R.,et al.E-cadherin germline mutation carriers:clinical management and genetic implications[J].Cancer Metastasis Rev.2014,33,1081-1094.
[8]Corso G.,Intra M.,Trentin C.,et al.CDH1 germline mutations and hereditary lobular breast cancer[J].Fam.Cancer,2016,15,215-219.
[9]El-Husny A.,Raiol-Moraes M.,Amador M.,et al.CDH1 mutations in gastric cancer patients from northern Brazil identified by Next- Generation Sequencing (NGS)[J].Genet.Mol.Biol.2016,39,189-198.
[10]Fewings E.,Larionov A.,Redman J.,et al.Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation:a whole-exome sequencing study[J].Lancet Gastroenterol.Hepatol.2018,3,489-498.
[11]Fornasarig M.,Magris R.,De Re V.,et al.Molecular and pathological features of gastric cancer in lynch syndrome and familial adenomatous polyposis[J].Int.J.Mol.Sci.2018,19:E1682.
[12]Gaston D.,Hansford S.,Oliveira C.,et al.Germline mutations in MAP3K6 are associated with familial gastric cancer[J].PLoS Genet.2014,10:e1004669.
[13]Godwin T.D.,Kelly S.T.,Brew T.P.,et al.E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation,dynamics and function[J].Gastric Cancer.2018,10.1007/s10120-018-0859-1[Epub ahead of print].
[14]Hamilton L.E.,Jones K.,Church N.,et al.Synchronous appendiceal and intramucosal gastric signet ring cell carcinomas in an individual with CDH1-associated hereditary diffuse gastric carcinoma:a case report of a novel association and review of the literature[J].BMC Gastroenterol.2013,13:114.
[15]Hansford S.,Kaurah P.,Li-Chang H.,et al.Hereditary diffuse gastric cancer syndrome:CDH1 mutations and beyond[J].JAMA Oncol.2015,1:23-32.
[16]Huang D.S.,Tao H.Q.,He X.J.,et al.Prevalence of deleterious ATM germline mutations in gastric cancer patients.Oncotarget 2015,6:40953-40958.
[17]Kievit A.,Tessadori F.,Douben H.,et al.Variants in members of the cadherin-catenin complex,CDH1 and CTNND1,cause blepharocheilodontic syndrome.Eur[J].J.Hum.Genet.2018,26:210-219.
[18]Kim D.H.,Son S.M.,Choi Y.J.Gastric metastasis from invasive lobular breast cancer,mimicking primary gastric cancer:a case report[J].Medicine 2018,97:e0258.
[19]Lee H.E.,Smyrk T.C.,Zhang L.Histologic and immunohistochemical differences between hereditary and sporadic diffuse gastric carcinoma[J].Hum.Pathol.2018,74,:64-72.(https://www.daowen.com)
[20]Lee Y.S.,Cho Y.S.,Lee G.K.,et al.Genomic profile analysis of diffuse-type gastric cancers[J].Genome Biol.2014,15:R55.
[21]Li D.,Lo W.,Rudloff U.Merging perspectives:genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin-EGFR crosstalk[J].Clin.Transl.Med.2018,7:7.
[22]Masciari S.,Dewanwala A.,Stoffel E.M.,et al.Gastric cancer in individuals with Li-Fraumeni syndrome[J].Genet.Med.2011,13:651-657.
[23]Melo S.,Figueiredo J.,Fernandes M.S.,et al.Predicting the functional impact of CDH1 missense mutations in hereditary diffuse gastric cancer[J].Int.J.Mol.Sci.2017,18:E2687.
[24]Moslim M.A.,Heald B.,Tu C.,et al.Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary diffuse gastric cancer[J].Surgery,2018,164:754-759.
[25]Park J.W.,Kim M.S.,Voon D.C.,et al.Multi-omics analysis identifies pathways and genes involved in diffuse-type gastric carcinogenesis induced by E-cadherin,p53,and Smad4 loss in mice[J].Mol.Carcinog.2018,57:947-954.
[26]Rocha J.P.,Gullo I.,Wen X.,et al.Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management[J].Histopathology,2018,73:878-886.
[27]Rona K.A.,Schwameis K.,Zehetner J.,et al.Gastric cancer in the young:An advanced disease with poor prognostic features.J.Surg.Oncol.2017,115:371-375.
[28]Van der Post R.S.,Gullo I.,Oliveira C.,et al.Histopathological,molecular,and genetic profile of hereditary diffuse gastric cancer:current knowledge and challenges for the future[J].Adv.Exp.Med.Biol.2016,908:371-391.
[29]Van der Post R.S.,Vogelaar I.P.,Carneiro F.,et al.Hereditary diffuse gastric cancer:updated clinical guidelines with an emphasis on germline CDH1 mutation carriers[J].J.Med.Genet.2015,52:361-374.
[30]Wang Z.,Graham D.Y.,Khan A.,et al.Incidence of gastric cancer in the USA during 1999 to 2013:a 50-state analysis[J].Int.J.Epidemiol.2018,47:966-975.
[31]Wright F.C.,Look Hong N.J.,Quan M.L.,et al.Indications for contralateral prophylactic mastectomy:a consensus statement using modified delphi methodology[J].Ann.Surg.2018,267:271-279.
[32]Gao K,Wu J.National trend of gastric cancer mortality in China(2003- 2015):a population- based study[J].Cancer Commun(Lond),2019,39(1):24.
[33]Laszkowska M,Silver ER,Schrope B,et al.Optimal timing of total gastrectomy to prevent diffuse gastric cancer in individuals with pathogenic variants in CDH1[J].Clin Gastroenterol Hepatol,2020,18(4):822-829 e4.
[34]Strong VE,Gholami S,Shah MA,et al.Total gastrectomy for hereditary diffuse gastric cancer at a single center:Postsurgical outcomes in 41 patients[J].Ann Surg,2017,266(6):1006-1012.
[35]Choi IJ,Kook MC,Kim YI,et al.Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer[J].N Engl J Med,2018,378(12):1085-1095.
[36]Tan MC,Graham DY.Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication:2020[J].Gastrointest Endosc,2019,90(3):457-460.
[37]Leone PJ,Mankaney G,Sarvapelli S,et al.Endoscopic and histologic features associated with gastric cancer in familial adenomatous polyposis[J].Gastrointest Endosc,2019,89(5):961-968.